Here’s the intro
The study targeted the reduction in frequency, intensity and duration of convulsive crises in people with tuberous sclerosis complex (TSC) and saw promising results from cannabidiol (CBD) as a treatment for patients with TSC. Other factors observed in the study were quality of life, dependence on heavy prescription drugs and long-term sustainability of treatment with CBD.
The trial was comprised of patients with varying forms of epilepsy, with the majority having TSC, a genetic disorder characterized by the growth of noncancerous (benign tumors) in many parts of the body, including the brain, which can lead to convulsive crises. TSC affects 1 million people worldwide, 50,000 in the U.S. and 20,000 in Mexico.